Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma

Annals of Surgical Oncology

Volumn 14, Issue 10, 2007, Pages 2748-2758

  Chou, Yuh Yu ^a,b   Jeng, Yung Ming ^c   Lee, Tan Tsao ^c   Hu, Fu Chang ^c   Kao, Hsin Lien ^c   Lin, Wei Chou ^c   Lai, Po Lin ^c   Hu, Rey Heng ^c   Yuan, Ray Hwang ^c,d  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d TAO YUAN GENERAL HOSPITAL   (Taiwan)

Author keywords

CD24; Diffuse type; Gastric adenocarcinoma; Lymphovascular invasion; Serosal invasion

Indexed keywords

CD24 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CELL MEMBRANE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RISK FACTOR; STOMACH ADENOCARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TUMOR THROMBUS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD24; CYTOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; SEROUS MEMBRANE; STOMACH; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34648820462     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9501-x     Document Type: Article

References (51)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108
2. Mercer DW, Robinson EK. Gastric neoplasia. In: Townsend CM Jr, Beauchamp RD, Evers BM, Mattox KL (eds.) Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice. 17th ed. Philadelphia: Elsevier Saunders, 2004:1265-321
3. Japanese Gastric Cancer Association Registration Committee, Maruyama K, Kaminishi M, Hayashi K, et al. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer 2006; 9:51-66
4. Hundahl SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Data Base report on gastric carcinoma. Cancer 1997; 80:2333-41
5. Serlin O, Keehn RJ, Higgins GA Jr, Harrower HW, Mendeloff GL. Factors related to survival following resection for gastric carcinoma: analysis of 903 cases. Cancer 1977; 40:1318-29
6. Adachi Y, Yasuda K, Inomata M, Sato K, Shiraishi N, Kitano S. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer 2000; 89:1418-24
7. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228:449-61
8. Werner M, Becker KF, Keller G, Hofler H. Gastric adenocarcinoma: pathomorphology and molecular pathology. J Cancer Res Clin Oncol 2001; 127:207-16
9. Pirruccello SJ, LeBien TW. The human B cell-associated antigen CD24 is a single chain sialoglycoprotein. J Immunol 1986; 136:3779-84
10. Fischer GF, Majdic O, Gadd S, Knapp W. Signal transduction in lymphocytic and myeloid cells via CD24, a new member of phosphoinositol-anchored membrane molecules. J Immunol 1990; 144:638-41
11. Sammar M, Aigner S, Hubbe M, Schirrmacher V, Schachner M, Vestweber D, Altevogt P. Heat-stable antigen (CD24) as ligand for mouse P-selectin. Int Immunol 1994; 6:1027-36
12. Chen M, Geng JG. P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp (Warsz) 2006; 54:75-84
13. Elghetany MT, Patel J. Assessment of CD24 expression on bone marrow neutrophilic granulocytes: CD24 is a marker for the myelocytic stage of development. Am J Hematol 2002; 71:348-9
14. Magnaldo T, Barrandon Y. CD24 (heat stable antigen, nectadrin), a novel keratinocyte differentiation marker, is preferentially expressed in areas of the hair follicle containing the colony-forming cells. J Cell Sci 1996; 109:3035-45
15. Shirasawa T, Akashi T, Sakamoto K, Takahashi H, Maruyama N, Hirokawa K. Gene expression of CD24 core peptide molecule in developing brain and developing non-neural tissues. Dev Dyn 1993; 198:1-13
16. Suzuki T, Kiyokawa N, Taguchi T, Sekino T, Katagiri YU, Fujimoto J. CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol 2001; 166:5567-77
17. Figarella-Branger D, Moreau H, Pellissier JF, Bianco N, Rougon G. CD24, a signal-transducing molecule expressed on human B lymphocytes, is a marker for human regenerating muscle. Acta Neuropathol (Berl) 1993; 86:275-84
18. Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 2004; 35:255-62
19. Su MC, Hsu C, Kao HL, Jeng YM. CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. Cancer Lett 2006; 235:34-9
20. Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, Altevogt P, Ley K. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 1998; 12:1241-51
21. Friederichs J, Zeller Y, Hafezi-Moghadam A, Grone HJ, Ley K, Altevogt P. The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res 2000; 60:6714-22
22. Jacob J, Bellach J, Grutzmann R, Alldinger I, Pilarsky C, Dietel M, Kristiansen G. Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades. Pancreatology 2004; 4:454-60
23. Hosmer DW, Lemeshow S. Applied Logistic Regression, 2nd ed. New York: John Wiley & Sons, 2000
24. Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: John Wiley & Sons, 1999
25. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Path Microbiol Scand 1965; 64:31-49
26. Lynch HT, Grady W, Suriano G, Huntsman D. Gastric cancer: new genetic developments. J Surg Oncol 2005; 90:114-33
27. Ming S. Cellular and molecular pathology of gastric carcinoma and precursor lesions: a critical review. Gastric Cancer 1998; 1:31-50
28. Roviello F, Marrelli D, Vindigni C, De Stefano A, Spina D, Pinto E. P53 accumulation is a prognostic factor in intestinal-type gastric carcinoma but not in the diffuse type. Ann Surg Oncol 1999; 6:739-45
29. Zheng H, Takahashi H, Murai Y, et al. Pathobiological characteristics of intestinal- and diffuse-type gastric carcinoma in Japan: An immunostaining study on the tissue microarray. J Clin Pathol 2007; 60:273-7
30. Weichert W, Denkert C, Burkhardt M, et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005; 11:6574-81
31. Lim SC, Oh SH. The role of CD24 in various human epithelial neoplasias. Pathol Res Pract 2005; 201:479-86
32. Sheen-Chen SM, Chou CW, Chen MC, Chen FC, Chen YS, Chen JJ. Adenocarcinoma in the middle third of the stomach-an evaluation for the prognostic significance of clinicopathological features. Hepatogastroenterology 1997; 44:1488-94
33. Ludeman L, Shepherd NA. Serosal involvement in gastrointestinal cancer: its assessment and significance. Histopathology 2005; 47:123-31
34. Miyashiro I, Takachi K, Doki Y, et al. When is curative gastrectomy justified for gastric cancer with positive peritoneal lavage cytology but negative macroscopic peritoneal implant? World J Surg 2005; 29:1131-4
35. Burke EC, Karpeh MS Jr, Conlon KC, Brennan MF. Peritoneal lavage cytology in gastric cancer: an independent predictor of outcome. Ann Surg Oncol 1998; 5:411-5
36. Jakl RJ, Miholic J, Koller R, Markis E, Wolner E. Prognostic factors in adenocarcinoma of the cardia. Am J Surg 1995; 169:316-9
37. Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002; 161:1215-21
38. Kristiansen G, Winzer KJ, Mayordomo E, et al. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 2003; 9:4906-13
39. Schindelmann S, Windisch J, Grundmann R, Kreienberg R, Zeillinger R, Deissler H. Expression profiling of mammary carcinoma cell lines: correlation of in vitro invasiveness with expression of CD24. Tumor Biol 2002; 23:139-45
40. Aigner S, Sthoeger ZM, Fogel M, et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997; 89:3385-95
41. Kristiansen G, Schluns K, Yongwei Y, Denkert C, Dietel M, Petersen I. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 2003; 88:231-6
42. Smith SC, Oxford G, Wu Z, et al. The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res 2006; 66:1917-22
43. Huang LR, Hsu HC. Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res 1995; 55:4717-21
44. Fogel M, Friederichs J, Zeller Y, et al. CD24 is a marker for human breast carcinoma. Cancer Lett 1999; 143:87-94
45. Sagiv E, Memeo L, Karin A, et al. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology 2006; 131:630-9
46. Baumann P, Cremers N, Kroese F, et al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 2005; 65:10783-93
47. Kruger JA, Kaplan CD, Luo Y, Zhou H, Markowitz D, Xiang R, Reisfeld RA. Characterization of stem cell-like cancer cells in immune-competent mice. Blood 2006; 108:3960-12
48. Shackleton M, Vaillant F, Simpson KJ, et al. Generation of a functional mammary gland from a single stem cell. Nature 2006; 439:84-8
49. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67:1030-7
50. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells: an integrated concept of malignant tumor progression. Nat Rev Cancer 2005; 5:744-9
51. Fischer A, Blanche S, Le Bidois J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324:1451-6